Suppr超能文献

利用重组表达和小鼠模型解码慢通道先天性肌无力综合征的发病机制

Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

作者信息

Otero-Cruz José David, Báez-Pagán Carlos Alberto, Dorna-Pérez Luisamari, Grajales-Reyes Gary Emanuel, Ramírez-Ordoñez Rosaura Teresa, Luciano Carlos A, Gómez Christopher Manuel, Lasalde-Dominicci José Antonio

机构信息

Department of Biology, University of Puerto Rico, Rio Piedras Campus, San Juan, PR.

出版信息

P R Health Sci J. 2010 Mar;29(1):4-17.

Abstract

Despite the fact that they are orphan diseases, congenital myasthenic syndromes (CMS) challenge those who suffer from it by causing fatigable muscle weakness, in the most benign cases, to a progressive wasting of muscles that may sentence patients to a wheelchair or even death. Compared to other more common neurological diseases, CMS are rare. Nevertheless, extensive research in CMS is performed in laboratories such as ours. Among the diverse neuromuscular disorders of CMS, we are focusing in the slow-channel congenital myasthenic syndrome (SCS), which is caused by mutations in genes encoding acetylcholine receptor subunits. The study of SCS has evolved from clinical electrophysiological studies to in vitro expression systems and transgenic mice models. The present review evaluates the methodological approaches that are most commonly employed to assess synaptic impairment in SCS and also provides perspectives for new approaches. Electrophysiological methodologies typically employed by physicians to diagnose patients include electromyography, whereas patient muscle samples are used for intracellular recordings, single-channel recordings and toxin binding experiments. In vitro expression systems allow the study of a particular mutation without the need of patient intervention. Indeed, in vitro expression systems have usually been implicated in the development of therapeutic strategies such as quinidine- and fluoxetine-based treatments and, more recently, RNA interference. A breakthrough in the study of SCS has been the development of transgenic mice bearing the mutations that cause SCS. These transgenic mice models have actually been key in the elucidation of the pathogenesis of the SCS mutations by linking IP-3 receptors to calcium overloading, as well as caspases and calpains to the hallmark of SCS, namely endplate myopathy. Finally, we summarize our experiences with suspected SCS patients from a local perspective and comment on one aspect of the contribution of our group in the study of SCS.

摘要

尽管先天性肌无力综合征(CMS)属于罕见病,但它给患者带来了诸多挑战,从最轻微的易疲劳性肌肉无力,到严重时肌肉逐渐萎缩,甚至可能使患者只能依靠轮椅行动,乃至死亡。与其他更常见的神经疾病相比,CMS较为罕见。然而,像我们实验室这样的机构仍在对CMS进行广泛研究。在CMS的各种神经肌肉疾病中,我们专注于慢通道先天性肌无力综合征(SCS),它是由编码乙酰胆碱受体亚基的基因突变引起的。对SCS的研究已从临床电生理研究发展到体外表达系统和转基因小鼠模型。本综述评估了最常用于评估SCS突触损伤的方法,并为新方法提供了展望。医生通常用于诊断患者的电生理方法包括肌电图检查,而患者的肌肉样本则用于细胞内记录、单通道记录和毒素结合实验。体外表达系统使我们能够在无需患者参与的情况下研究特定突变。事实上,体外表达系统通常参与了基于奎尼丁和氟西汀等治疗策略的开发,以及最近的RNA干扰技术。SCS研究中的一项突破是培育出携带导致SCS突变的转基因小鼠。这些转基因小鼠模型实际上在阐明SCS突变的发病机制方面发挥了关键作用,它们将IP - 3受体与钙超载联系起来,同时将半胱天冬酶和钙蛋白酶与SCS的标志,即终板肌病联系起来。最后,我们从本地角度总结了对疑似SCS患者的研究经验,并对我们团队在SCS研究中的贡献的一个方面进行了评论。

相似文献

2
Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome.
J Neurosci. 2002 Aug 1;22(15):6447-57. doi: 10.1523/JNEUROSCI.22-15-06447.2002.
3
A mouse model of the slow channel myasthenic syndrome: Neuromuscular physiology and effects of ephedrine treatment.
Exp Neurol. 2013 Oct;248:286-98. doi: 10.1016/j.expneurol.2013.06.012. Epub 2013 Jun 21.
4
[Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
Rev Neurol (Paris). 2004 Feb;160(2):163-76. doi: 10.1016/s0035-3787(04)70887-5.
7
Zebrafish model for congenital myasthenic syndrome reveals mechanisms causal to developmental recovery.
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17711-6. doi: 10.1073/pnas.1215858109. Epub 2012 Oct 8.
8
Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome.
Exp Neurol. 2015 Aug;270:88-94. doi: 10.1016/j.expneurol.2014.10.008. Epub 2014 Oct 23.

本文引用的文献

1
Congenital myasthenic syndromes.
Handb Clin Neurol. 2008;91:285-331. doi: 10.1016/S0072-9752(07)01510-2.
3
The therapy of congenital myasthenic syndromes.
Neurotherapeutics. 2007 Apr;4(2):252-7. doi: 10.1016/j.nurt.2007.01.001.
6
Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model.
Neurobiol Dis. 2006 Aug;23(2):462-70. doi: 10.1016/j.nbd.2006.04.018. Epub 2006 Jul 11.
8
Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation.
Mol Cell Neurosci. 2006 May-Jun;32(1-2):82-90. doi: 10.1016/j.mcn.2006.02.004. Epub 2006 Apr 19.
9
Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine.
Neuromuscul Disord. 2006 May;16(5):329-33. doi: 10.1016/j.nmd.2006.02.009. Epub 2006 Apr 18.
10
Molecular architecture of the neuromuscular junction.
Muscle Nerve. 2006 Apr;33(4):445-61. doi: 10.1002/mus.20440.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验